BML Capital Management LLC Invests $35,000 in HilleVax, Inc. (NASDAQ:HLVX)

BML Capital Management LLC bought a new stake in HilleVax, Inc. (NASDAQ:HLVX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 19,760 shares of the company’s stock, valued at approximately $35,000. HilleVax comprises about 0.0% of BML Capital Management LLC’s investment portfolio, making the stock its 29th biggest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of HLVX. Frazier Life Sciences Management L.P. boosted its position in HilleVax by 8.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock worth $153,523,000 after purchasing an additional 835,590 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of HilleVax in the second quarter valued at about $6,960,000. Tidal Investments LLC purchased a new stake in shares of HilleVax during the 1st quarter valued at about $207,000. Trium Capital LLP purchased a new stake in shares of HilleVax during the 3rd quarter valued at about $798,000. Finally, Maven Securities LTD acquired a new position in HilleVax during the 2nd quarter worth approximately $217,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of HilleVax in a research report on Monday, August 12th. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.20.

HilleVax Stock Performance

Shares of NASDAQ HLVX traded down $0.01 during mid-day trading on Tuesday, reaching $1.97. The company had a trading volume of 6,544 shares, compared to its average volume of 436,706. The stock’s 50 day moving average is $1.81 and its 200-day moving average is $6.09. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The stock has a market capitalization of $97.83 million, a PE ratio of -0.64 and a beta of 0.78.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). On average, sell-side analysts anticipate that HilleVax, Inc. will post -2.47 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.